2-(2,2-difluoro-1,3-benzodioxol-4-yl)-N-(1-methyl-1H-tetrazol-5-yl)-7-azaspiro[3.5]nonane-7-carboxamide | 1225275-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2-(2,2-difluoro-1,3-benzodioxol-4-yl)-N-(1-methyl-1H-tetrazol-5-yl)-7-azaspiro[3.5]nonane-7-carboxamide
• 英文别名: 2-(2,2-difluoro-1,3-benzodioxol-4-yl)-N-(1-methyltetrazol-5-yl)-7-azaspiro[3.5]nonane-7-carboxamide
• CAS: 1225275-99-9
• 化学式: C₁₈H₂₀F₂N₆O₃
• 分子量: 406.392
• InChiKey: PLEUBWXWTVGJOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  94.4
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS
  申请人：Long Scott A.

  公开号：US20100113465A1

  公开（公告）日：2010-05-06

  Provided herein are 7-azaspiro[3.5]nonane-7-carboxamide compounds and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, cancer and cancer pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, lupus, diabetes, allergic asthma, vascular inflammation, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.

  本文提供了7-azaspiro[3.5]nonane-7-carboxamide化合物及其药用可接受盐，用于治疗与脂肪酸酰胺水解酶（FAAH）活性相关的疾病或症状，包括急性疼痛、慢性疼痛、神经病性疼痛、伤害性疼痛、炎症性疼痛、癌症及癌症疼痛、纤维肌痛、类风湿性关节炎、炎症性肠病、狼疮、糖尿病、过敏性哮喘、血管炎症、尿失禁、膀胱过度活跃、呕吐、认知障碍、焦虑、抑郁、睡眠障碍、进食障碍、运动障碍、青光眼、牛皮癣、多发性硬化、脑血管疾病、脑损伤、胃肠道疾病、高血压或心血管疾病。
• [EN] 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] COMPOSÉS 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMME MODULATEURS DE L'HYDROLASE D'AMIDES D'ACIDES GRAS
  申请人：PFIZER

  公开号：WO2010049841A1

  公开（公告）日：2010-05-06

  Provided herein are 7-azaspiro[3.5]nonane-7-carboxamide compounds and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, cancer and cancer pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, lupus, diabetes, allergic asthma, vascular inflammation, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.

  本文提供了7-azaspiro[3.5]nonane-7-carboxamide化合物及其药学上可接受的盐，用于治疗与脂肪酸酰胺水解酶（FAAH）活性相关的疾病或症状，包括急性疼痛、慢性疼痛、神经病理性疼痛、伤害性疼痛、炎症性疼痛、癌症和癌痛、纤维肌痛、类风湿性关节炎、炎症性肠病、狼疮、糖尿病、过敏性哮喘、血管炎症、尿失禁、膀胱过度活动、呕吐、认知障碍、焦虑、抑郁、睡眠障碍、进食障碍、运动障碍、青光眼、银屑病、多发性硬化症、脑血管疾病、脑损伤、胃肠道疾病、高血压或心血管疾病。
• 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase
  申请人：Pfizer Inc.

  公开号：EP2358704A1

  公开（公告）日：2011-08-24